Bordetella pertussis
520
The bacterium contains a surface protein, filamentous hemagglutinin, which binds to sulfatides that are found on cilia of epithelial cells. Once anchored, the bacterium produces tracheal cytotoxin, which stops the cilia from beating. This prevents the cilia from clearing debris from the lungs, so the body responds by sending the host into a coughing fit. These coughs expel some bacteria into the air, which are free to infect other hosts. Bordetella pertussis has the ability to inhibit the function of the host's immune system. Two toxins, known as the pertussis toxin (or PTx) and adenylate cyclase (CyaA), are responsible for this inhibition. CyaA converts ATP to cyclic AMP, and PTx inhibits an intracellular protein that regulates this process. The end result is that phagocytes convert too much ATP to cyclic AMP, which can cause disturbances in cellular signaling mechanisms, and prevent phagocytes from correctly responding to an infection (Wiki: Bordetella pertussis).
Whooping Cough
Acellular pertussis vaccines are effective in providing immunity to whooping cough, by stimulating antibodies to pertussis toxins, as well as an adhesin (Salyers and Whitt., 2002).
Animal models of pertussis include primates, rats, mice, and rabbits (Salyers and Whitt., 2002).
Bordetella pertussis is a Gram-negative, aerobic coccobacillus of the genus Bordetella, and the causative agent of pertussis or whooping cough. Pertussis (or Whooping Cough), is an infection of the respiratory system and characterized by a “whooping” sound when the person breathes in. In the US it killed 5,000 to 10,000 people per year before a vaccine was available. Vaccination has transformed this and between 1985-88 fewer than 100 children died from pertussis. Worldwide in 2000, according to the WHO, around 39 million people were infected annually and about 297,000 died. Bordetella pertussis infects its host by colonizing lung epithelial cells. The infection occurs most with children under the age of one when they are unimmunized or children with faded immunity, normally around the age 11 through 18. The signs and symptoms are similar to a common cold: runny nose, sneezing, mild cough, and low-grade fever. The patient becomes most contagious during the catarrhal stage of infection, normally 2 weeks after the coughing begins. It may become airborne when the person coughs, sneezes, or laughs. Pertussis vaccine is part of the DTaP (diphtheria, tetanus, acellular pertussis) immunization. The paroxysmal cough precedes a crowing inspiratory sound characteristic of pertussis. After a spell, the patient might make a “whooping” sound when breathing in, or vomit. Adults have milder symptoms, like prolonged coughing without the “whoop.” Infants less than 6 months may not have the typical whoop. A coughing spell may last a minute or more, producing cyanosis, apnoea and seizures. However, when not in a coughing fit, the patient does not experience trouble breathing. This is because Bordetella pertussis inhibits the immune response and therefore very little mucus is generated in the lungs. A prolonged cough may be irritating and sometimes a disabling cough may go undiagnosed in adults for many months (Wiki: Bordetella pertussis).
Baboon
Papio cynocephalus
9556
Bank vole
Clethrionomys glareolus
447135
Bear
Ursus americanus
9643
Birds
Passeroidea
175121
Brown Trout
Salmo trutta
8032
Buffalo
Bison bison
9901
Carnivores
Vulpes
9625
Cat
Felis catus
9685
Catfishes
Siluriformes
7995
Cattle
Bos taurus
9913
Chicken
Gallus gallus
9031
Chimpanzee
Pan troglodytes
9598
chinchillas
Chinchillidae
10150
Copper Pheasant
Syrmaticus soemmerringii
9067
Deer
Cervus elaphus
9860
Deer mouse
Peromyscus maniculatus
10042
Dog
Canis familiaris
9615
Ducks
Anas
8835
Ferret
Mustela putorius furo
9669
Fish
Hyperotreti
117565
Gerbil
Gerbillina
10045
Goat
Capra hircus
9925
Gray wolf
Canis lupus
9612
Guinea pig
Cavia porcellus
10141
Hamster
Mesocricetus auratus
10036
Horse
Equus caballus
9796
Human
Homo sapiens
9606
Macaque
Macaca fascicularis
9541
Mongolian Gerbil
Meriones unguiculatus
10047
Monkey
Platyrrhini
9479
Mouse
Mus musculus
10090
None
None
Parrot
Psittacidae
9224
Pig
Sus scrofa
9823
Rabbit
Oryctolagus cuniculus
9986
Rainbow trout
Oncorhynchus mykiss
8022
Rat
Rattus
10114
Raven
Corvus corax
56781
sei whale
Balaenoptera borealis
9768
Sheep
Ovis aries
9940
Squirrel
Spermophilus richardsonii
37591
Tree shrew
Tupaiidae
9393
Trouts, salmons & chars
Salmoninae
504568
Turkey
Meleagris gallopavo
9103
Vole
Microtus ochrogaster
79684
Water buffalo
Bubalus bubalis
391902
Actacel
Diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b conjugate vaccine
Actacel
Sanofi Pasteur Ltd
VO_0010705
Subunit vaccine
Licensed
Intramuscular injection (i.m.)
Canada
Products: Proteins + Conjugate.
Aluminum phosphate
Refrigerate at 2° to 8°C.
Intramuscular injection (i.m.)
Adacel
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed
Adacel
Sanofi Pasteur, Ltd (USA: License #1726)
VO_0000005
Toxoid vaccine
Licensed
Intramuscular injection (i.m.)
USA: License #1726; Canada
It is a sterile liquid suspension of tetanus and diphtheria toxoids and acellular pertussis components adsorbed onto aluminum phosphate, for intramuscular administration.
aluminum phosphate
Adacel vaccine should be stored at 2° to 8°C (35° to 46°F). DO NOT FREEZE
Clostridium tetani is grown in modified Mueller-Miller casamino acid medium without beef heart infusion. Tetanus toxin is detoxified with formaldehyde and purified by ammonium sulfate fractionation and diafiltration. Diphtheria and tetanus toxoids are individually adsorbed onto aluminum phosphate (FDA: Adacel).
Intramuscular injection (i.m.)
Pertussis
Adacel-Polio
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine
Adacel-Polio
Sanofi Pasteur SA
Toxoid vaccine + Subunit vaccine + Inactivated or "killed" vaccine
Licensed
Intramuscular injection (i.m.)
Canada
ADACEL®-POLIO is a sterile, uniform, cloudy, white suspension of tetanus and diphtheria toxoids and acellular pertussis vaccine adsorbed separately on aluminum phosphate and combined with inactivated poliomyelitis vaccine (vero cell origin) types 1, 2 and 3, and suspended in water for injection. Acellular pertussis vaccine is composed of five purified pertussis antigens (PT, FHA, PRN and FIM). (Product Monograph: Adacel-Polio)
Aluminum phosphate
Store at 2° to 8°C (35° to 46°F), do not freeze.
Intramuscular injection (i.m.)
B. pertussis BrkA protein vaccine
VO_0011377
Subunit vaccine
Research
Subcutaneous injection
Subcutaneous injection
B. pertussis brkA
Recombinant protein preparation
Fraction BS was applied to a Mono Q Sepharose (Amersham, Biosciences) (0.5 mg protein per ml resin) previously equilibrated with 25 mM Tris–HCl, pH 8.0. Proteins were eluted with a NaCl gradient (0–1 M) in 25 mM Tris–HCl, pH 8.0, in 0.5 ml fractions at a flow rate of 1 ml/min. Elution was monitored at A280 nm. The fractions showing the same peak profile were pooled and eluted again under the same chromatography conditions. Samples were submitted to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (T = 12.5% in 0.75 M Tris, 0.2% SDS, pH 8.8) and electrophoresis was performed at 60 mA in 25 mM Tris, 0.192 M glycine, 0.1% SDS, pH 8.3. The gel was stained with silver nitrate and fractions showing a similar molecular mass profile were pooled, concentrated by centrifugation at 440 × g in Centrifugal Ultrafree-20 tubes, 10 kDa (Millipore), and their protein concentration was evaluated. Four pools were formed (P1, P2, P3, P4), and used for immunization of mice (Cainelli et al., 2007).
BALB/c
Female BALB/c mice, 4–6 weeks old (Animal House of the Instituto Butantan) (9–15 mice/group) were subcutaneously injected three times at weekly intervals (days 0, 7, 14) with BS pools (P1, P2, P3, P4) (1 μg/0.1 ml/mouse), and two times (days 0 and 14) with 73 kDa or 60 kDa proteins (1 μg/0.1 ml/mouse) alone or mixed with Diphtheria-Pertussis-Tetanus (DPT) vaccine formulated without aluminum hydroxide (NA-DPT), (2 μl/mouse), (Instituto Butantan). Current DPT vaccine containing aluminum hydroxide (DPTBut) was used as control (2 μl/mouse) (Lot no. 0008147/0 and 0309132, Instituto Butantan). Non-immunized mice (injected with physiologic saline) were used as control (Cainelli et al., 2007).
High levels of antibodies were induced, and a 78% protection rate of mice challenged with live B. pertussis was observed. The 73 kDa N-terminal alpha-domain of BrkA autotransporter protein, one protein identified in the fraction, stimulated antibodies against pertussis and induced a 42% protection rate against the challenge (Cainelli et al., 2007).
Animals were challenged by intracerebral route (i.c.) with live B. pertussis (strain 18323, NIH, USA), 21 days after the first immunization. Each mouse was inoculated with 30,000 live bacteria. Deaths were recorded until day 15 (Cainelli et al., 2007).
B. pertussis Cpn60 protein vaccine
VO_0011357
Subunit vaccine
Research
Subcutaneous injection
Subcutaneous injection
B. pertussis cpn60/60 kDa chaperonin
Recombinant protein preparation
Fraction BS was applied to a Mono Q Sepharose (Amersham, Biosciences) (0.5 mg protein per ml resin) previously equilibrated with 25 mM Tris–HCl, pH 8.0. Proteins were eluted with a NaCl gradient (0–1 M) in 25 mM Tris–HCl, pH 8.0, in 0.5 ml fractions at a flow rate of 1 ml/min. Elution was monitored at A280 nm. The fractions showing the same peak profile were pooled and eluted again under the same chromatography conditions. Samples were submitted to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (T = 12.5% in 0.75 M Tris, 0.2% SDS, pH 8.8) and electrophoresis was performed at 60 mA in 25 mM Tris, 0.192 M glycine, 0.1% SDS, pH 8.3. The gel was stained with silver nitrate and fractions showing a similar molecular mass profile were pooled, concentrated by centrifugation at 440 × g in Centrifugal Ultrafree-20 tubes, 10 kDa (Millipore), and their protein concentration was evaluated. Four pools were formed (P1, P2, P3, P4), and used for immunization of mice (Cainelli et al., 2007).
BALB/c
Female BALB/c mice, 4–6 weeks old (Animal House of the Instituto Butantan) (9–15 mice/group) were subcutaneously injected three times at weekly intervals (days 0, 7, 14) with BS pools (P1, P2, P3, P4) (1 μg/0.1 ml/mouse), and two times (days 0 and 14) with 73 kDa or 60 kDa proteins (1 μg/0.1 ml/mouse) alone or mixed with Diphtheria-Pertussis-Tetanus (DPT) vaccine formulated without aluminum hydroxide (NA-DPT), (2 μl/mouse), (Instituto Butantan). Current DPT vaccine containing aluminum hydroxide (DPTBut) was used as control (2 μl/mouse) (Lot no. 0008147/0 and 0309132, Instituto Butantan). Non-immunized mice (injected with physiologic saline) were used as control (Cainelli et al., 2007).
High levels of antibodies were induced, and a 78% protection rate of mice challenged with live B. pertussis was observed. The Cpn60/60 kDa chaperonin, one protein identified in the fraction, stimulated antibodies against pertussis and induced a 42% protection rate against the challenge (Cainelli et al., 2007).
Animals were challenged by intracerebral route (i.c.) with live B. pertussis (strain 18323, NIH, USA), 21 days after the first immunization. Each mouse was inoculated with 30,000 live bacteria. Deaths were recorded until day 15 (Cainelli et al., 2007).
B. pertussis CyaA protein vaccine
VO_0011359
Subunit vaccine
Research
Subcutaneous injection
Subcutaneous injection
B. pertussis secreted adenylate cyclase (cyaA)
Recombinant protein preparation
The AC was purified from culture supernatants using a camodulin affinity chromatography. The preparation consisted of two polypeptides of 45 and 43 kDa that are structurally related as described by Ladant et al (Guiso et al., 1989).
BALB/c
For active immunizations, Balb/c mice were given, subcutaneously, 3,ug of purified AC adsorbed on aluminium hydroxide, three times, at one week intervals . The mice were bled 5 days after the last injection in order to assess the presence of circulating anti-AC antibodies . The lethal challenge was performed 9 days after the final injection (Guiso et al., 1989).
Active immunization with purified B. pertussis secreted adenylate cyclase (cyaA) protect mice against a lethal respiratory challenge with B. pertussis or B. parapertussis (Guiso et al., 1989).
Bacterial suspension (50 pl) was injected intranasally to groups of 10 3-week-old female Balb/c mice (CERJ, St Berthevin, France), weighing 16±1 g . The LD 50 for the challenge inocula was determined daily by recording the number of dead mice . Pulmonary edema was quantified by lung weight (Guiso et al., 1989).
B. pertussis DNA vaccine encoding Prn
VO_0011391
DNA vaccine
Research
DONR221 (Invitrogen, Carlsbad, CA) and pABB-CRS2 [Ref1021:Komatsu et al., 2010].
Subcutaneous injection
Subcutaneous injection
B. pertussis pertactin precursor prn2
DNA vaccine construction
To construct a prn mutant, amplification of the region containing the whole prn2 gene of the CCHMC1 strain was performed using PRN-F GGCACAGGACCGGCGCGTGTTTCGCGCACGACTCT) and PRN-R (CGCGTGGTGCGCCTGAAAGGCGGCGATGCCTTCA) with attB adaptors. The PCR products were cloned into pDONR221 to obtain pDONR-PTXA1 and pDONR-PRN2 by site-specific recombination techniques using the Gateway cloning system (Invitrogen). The regions transferred into the pDONR221 plasmid were sequenced for verification. pDONR-PTXA1 or pDONR-PRN2 was mixed with pABB-CRS2 to obtain pABB-PTXA1 and pABB-PRN2 by using the Gateway cloning system. pABB-PTXA1 or pABB-PRN2 was introduced into E. coli SM10pir and mobilized into the B. pertussis strain Tohama by conjugation (Komatsu et al., 2010).
BALB/c
3.5-week-old female BALB/c mice (Japan SLC, Hamamatsu) were immunized by two subcutaneous injections of 0.25 SHDs (0.125 ml) over a 2-week interval (Komatsu et al., 2010).
While the vaccine was effective against all of the B. pertussis strains regardless of the allele expression pattern, the strain expressing ptxA1 and prn2 displayed a survival advantage over the other strains (Komatsu et al., 2010).
Two weeks after the second immunization, 50 µl of a suspension containing approximately 6 x 10^6 CFU of B. pertussis was instilled intranasally into mice anesthetized by intraperitoneal injection with pentobarbital sodium (Nembutal; Abbott Laboratories, Abbott Park, IL). Two hours (day 0) or 2, 5, or 8 days after the challenge, the mice were euthanized by pentobarbital injection (Komatsu et al., 2010).
B. pertussis DNA vaccine pcDNA/S1
VO_0004545
DNA vaccine
Research
pcDNA.3.1(+) [Ref2663:Kamachi et al., 2003]
Gene gun
Gene gun
DNA vaccine construction
Gene gun vaccination was employed for the delivery of pcDNA/S1, and the induction of IgG1 predominant antibody production was observed (Kamachi et al., 2003).
For immunization, 0.5 mg of gold particles were coated with 2 μg of plasmid DNA and 0.5 mg gold per injection was used. Mice were immunized intradermally three times on days 0, 14, and 28 using a Helios Gene Gun at a helium gas pressure of 400 psi (Kamachi et al., 2003).
In the pcDNA/S1-immune group, five out of 10 mice survived 24 hours after the challenge, whereas all of the mice in the pcDNA-immune group died within 24 hours (Kamachi et al., 2003).
Immunized BALB/c mice were challenged intranasally with B. pertussis strain 18–323 (Kamachi et al., 2003).
B. pertussis FhaB and 69 kDa OMP protein vaccine
VO_0011498
Subunit vaccine
Research
Intramuscular injection (i.m.)
4.0 ml Alhydrogel (Novotny et al., 1991)
Intramuscular injection (i.m.)
Combination of the B. pertussis 69-kDa outer membrane protein and filamentous hemagglutinin (fhaB)
Recombinant protein preparation
A crystal clear supernatant of 5-day-old static cultures containing proteolysis inhibitor was purified. To remove impurities, the FHA was precipitated by overnight dialysis against 25-30 volumes of buffer A at 4 C, and the precipitate was collected by centrifugation. The precipitated FHA was dissolved in the smallest possible volume of 40 mM B-alanine buffer at pH 3.5, clarified by centrifugation, and applied at room temperature at a flow of 30 ml/h to a Superose 12 column. The retained highly purified FHA was eluted (Novotny et al., 1991).
Groups of mice were injected intraperitoneally with 0.5 ml volumes of four concentrations (Novotny et al., 1991).
A combination of the 69-kDa outer membrane protein and filamentous hemagglutinin (fhaB), both isolated from lymphocytosis promoting factor (LPF; pertussis toxin) minus mutants of Bordetella pertussis, is protective in the mouse intracerebral challenge potency (Kendrick) test (Novotny et al., 1991).
Mice were challenged intracerebrally 14 days after antigen injection. The challenge dose contained 300-400 LD50, and a 1:1250 dilution of the challenge does contained ~ 10cfu. All mice were challenged within 90 minutes after the challenge suspension was thawed; the challenge was injected using a 1 ml syringe in a Hamilton PB600-I dispensor that reproducibly delivers 20-ul voumes (Novotny et al., 1991).
B. pertussis PTx protein vaccine
VO_0011361
Subunit vaccine
Research
Intraperitoneal injection (i.p.)
Aluminum hydroxide
Intraperitoneal injection (i.p.)
B. pertussis pertussis toxin (PTx)
Recombinant protein preparation
Vaccine is prepared by chemically modifying purified PT from culture supernatants with tetranitromethane (TNM). The lot was adsorbed to aluminum hydroxide (Alhydogel; Superfos, Vedbaek, Denmark) at a concentration of 50 μg of protein adsorbed to 4 mg per 1.0 ml. Animal doses (2.5, 0.5, and 0.1 μg) were prepared by making fivefold serial dilutions in aluminum hydroxide (4 mg/ml) diluent and given in a volume of 50 μl (Bruss and Siber, 2002).
Recombinant protein preparation
Vaccine is prepared by chemically modifying purified PT from culture supernatants with tetranitromethane (TNM). The lot was adsorbed to aluminum hydroxide (Alhydogel; Superfos, Vedbaek, Denmark) at a concentration of 50 μg of protein adsorbed to 4 mg per 1.0 ml. Animal doses (2.5, 0.5, and 0.1 μg) were prepared by making fivefold serial dilutions in aluminum hydroxide (4 mg/ml) diluent and given in a volume of 50 μl (Bruss and Siber, 2002).
Recombinant protein preparation
Vaccine is prepared by chemically modifying purified PT from culture supernatants with tetranitromethane (TNM). The lot was adsorbed to aluminum hydroxide (Alhydogel; Superfos, Vedbaek, Denmark) at a concentration of 50 μg of protein adsorbed to 4 mg per 1.0 ml. Animal doses (2.5, 0.5, and 0.1 μg) were prepared by making fivefold serial dilutions in aluminum hydroxide (4 mg/ml) diluent and given in a volume of 50 μl (Bruss and Siber, 2002).
Recombinant protein preparation
Vaccine is prepared by chemically modifying purified PT from culture supernatants with tetranitromethane (TNM). The lot was adsorbed to aluminum hydroxide (Alhydogel; Superfos, Vedbaek, Denmark) at a concentration of 50 μg of protein adsorbed to 4 mg per 1.0 ml. Animal doses (2.5, 0.5, and 0.1 μg) were prepared by making fivefold serial dilutions in aluminum hydroxide (4 mg/ml) diluent and given in a volume of 50 μl (Bruss and Siber, 2002).
Recombinant protein preparation
Vaccine is prepared by chemically modifying purified PT from culture supernatants with tetranitromethane (TNM). The lot was adsorbed to aluminum hydroxide (Alhydogel; Superfos, Vedbaek, Denmark) at a concentration of 50 μg of protein adsorbed to 4 mg per 1.0 ml. Animal doses (2.5, 0.5, and 0.1 μg) were prepared by making fivefold serial dilutions in aluminum hydroxide (4 mg/ml) diluent and given in a volume of 50 μl (Bruss and Siber, 2002).
BALB/c
Mice were removed from their cages, weighed, and placed on a stainless steel rack that fits inside of the Plexiglas aerosol chamber (40 by 40 by 40 cm). The 21-h culture of B. pertussis was suspended in sterile PBS to a concentration of approximately 2 × 10^9 CFU/ml of inoculum. This inoculum was delivered to the mice using a standard nebulizer (model 647; Devilbis, Somerset, Pa.) with a set pressure of 1.5 kg/cm2. The chamber and the nebulizer were enclosed in a biosafety level-2 hood and certified prior to use to document that airflow barriers were maintained. Uniformity of aerosol in the chamber was maintained with the use of two PABST 900 series AC fans (Newark Supply, Newark, N.J.). The even dispersion of the aerosol was confirmed with a light laser (Bruss and Siber, 2002).
BALB/c mice were immunized with PTx vaccine on day 6 of life and then challenged with B. pertussis using the aerosol challenge model. These primed mice were significantly better protected against leukocytosis, weight loss, and proliferation of B. pertussis in the lungs following aerosol challenge than the nonprimed group. This protection correlated with levels of anti-PT antibody in serum present on the day of aerosol challenge (Bruss and Siber, 2002).
Mice were exposed to nebulization for 30 min and removed 30 min after termination of aerosol. The completion of the aerosol represented time 0. Mice were removed from the box and replaced into their cages. Cages were checked daily for mortality (Bruss and Siber, 2002).
Boostrix
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed
Boostrix
GlaxoSmithKline Biologicals
VO_0000015
Toxoid vaccine
Licensed
Intramuscular injection (i.m.)
USA (License #1617)
BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) is a noninfectious, sterile, vaccine for intramuscular administration. It contains tetanus toxoid, diphtheria toxoid, and pertussis antigens (inactivated pertussis toxin [PT] and formaldehyde-treated filamentous hemagglutinin [FHA] and pertactin). The antigens are the same as those in INFANRIX, but BOOSTRIX is formulated with reduced quantities of these antigens (FDA: Boostrix).
Aluminum Phosphate
Store refrigerated between 2º and 8ºC (36º and 46ºF). Do not freeze.
Tetanus toxin is produced by growing Clostridium tetani in a modified Latham medium derived from bovine casein. Toxins are detoxified with formaldehyde, concentrated by ultrafiltration, and purified by precipitation, dialysis, and sterile filtration (FDA: Boostrix).
Intramuscular injection (i.m.)
Boostrix-Polio
Combined diphtheria, tetanus, acellular pertussis (adsorbed) and inactivated poliomyelitis vaccine
Boostrix-Polio
GlaxoSmithKline
Toxoid vaccine + Subunit vaccine + Inactivated or "killed" vaccine
Licensed
Intramuscular injection (i.m.)
Canada
BOOSTRIX®-POLIO (combined diphtheria, tetanus, acellular pertussis and inactivated poliomyetitis) vaccine contains diphtheria toxoid, tetanus toxoid, three purified pertussis antigens [pertussis toxoid (PT), filamentous haemagglutinin (FHA) and pertactin (69 kDalton outer membrane protein)] adsorbed onto aluminum salts and inactivated polio virus types 1, 2 and 3. (GSK: Boostrix-Polio)
Aluminum hydroxide
Store at 2° to 8°C (35° to 46°F), do not freeze.
Intramuscular injection (i.m.)
Bordetella pertussis aroA mutant vaccine
VO_0002807
Live, attenuated vaccine
Research
intracerebral challenge
A DNA fragment encoding a kanamycin resistance determinant was used to insertionally inactivate the cloned aroA gene of Bordetella pertussis in Escherichia coli K-12, and a conjugative shuttle vector system based on the suicide vector pRTP1 was used to deliver the mutations from E. coli back into B. pertussis CN2992FS and BP1. The aroA mutation was introduced by allelic exchange into the chromosome of B. pertussis, resulting in otherwise isogenic parental and aroA mutant pairs. The B. pertussis aroA mutants grew well on laboratory medium supplemented with aromatic compounds but failed to grow on unsupplemented medium (Roberts et al., 1990).
intracerebral challenge
Gene mutation
The B. pertussis aroA mutants expressed the normal B. pertussis extracellular, virulence-associated proteins (Roberts et al., 1990).
Mice exposed to three separate aerosols of live B. pertussis aroA bacteria were protected against lung colonization after being exposed to an aerosol containing the virulent parental B. pertussis strain. High-level antibodies against B. pertussis rapidly appeared in the sera of mice immunized by aerosol with the B. pertussis aroA strains and challenged with the virulent parent (Roberts et al., 1990).
Bordetella pertussis BPZE vectored vaccine
VO_0004608
Recombinant vector vaccine
Research
Bordetella pertussis BPZE, which is attenuated for 3 different toxins: the pertussis toxin, the dermonecrotic toxin, and the tracheal cytotoxins [Ref2891:Mielcarek et al., 2006].
intranasal immunization
This is an intranasal vaccine because pathogenic B. pertussis colonizes the respiratory tract of humans. The vaccine itself has been shown to only need one inoculation in order to elicit protection, making it a good candidate to be a vaccine vector for other diseases (Mielcarek et al., 2006).
The pertussis toxin itself if extremely virulent, but after thorough and careful attenuation, the virulence is basically gone (Mielcarek et al., 2006).
intranasal immunization
The pertussis toxin gene, which encodes a highly virulent toxin (Mielcarek et al., 2006).
The mice were vaccinated with highly-attenuated B. pertussis in order to prepare for challenge with virulent wild-type B. pertussis (Mielcarek et al., 2006).
VO_0000287
A single intranasal inoculation of mice with the B. pertussis vaccine vector induced the same level of protection, if not higher, as two injections of the commercial acellular vaccine (Mielcarek et al., 2006) .
After the mice had been inoculated with attenuated B. pertussis (which after a month had colonized the entire mouse respiratory tract) they were challenged with virulent wild-type B. pertussis (Mielcarek et al., 2006).
Inoculation with the B. pertussis vaccine vector shows protective immunity which rivals that of the vaccines currently on the market.
Bordetella pertussis dnt mutant vaccine
VO_0002808
Live, attenuated vaccine
Research
intranasal immunization
his strain was obtained by genetically inactivating pertussis toxin via two point mutations in the ptx gene, by deleting dnt encoding dermonecrotic toxin, and by replacing the B. pertussis ampG gene by Escherichia coli ampG, resulting in the removal of tracheal cytotoxin (Feunou et al., 2008).
intranasal immunization
Gene mutation
The dnt mutant in B. pertussis yielded a highly attenuated strain that was still able to transiently colonize the mouse respiratory tract [Ref1805:Feunou et al., 2008.
A single intranasal administration of BPZE1(dnt mutant vaccine) induced full protection in adult mice (8 weeks old), as well as in infant mice (3 weeks old), whereas commercial acellular pertussis vaccine (aPV) only partially protected infant mice, even after repetitive doses (Feunou et al., 2008).
DAPTACEL
Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
DAPTACEL
Sanofi Pasteur, Ltd.
VO_0000029
Toxoid vaccine
Licensed
Intramuscular injection (i.m.)
USA (License #1726)
DAPTACEL is a vaccine indicated for active immunization against diphtheria, tetanus and pertussis as a five-dose series in infants and children 6 weeks through 6 years of age.
aluminum phosphate
Should be stored at 2° to 8°C (35° to 46°F). DO NOT FREEZE.
Clostridium tetani is grown in modified Mueller-Miller casamino acid medium without beef heart infusion. Tetanus toxin is detoxified with formaldehyde and purified by ammonium sulfate fractionation and diafiltration (FDA: DAPTACEL).
Intramuscular injection (i.m.)
Isotonic suspension of pertussis antigens and diphtheria and tetanus toxoids (FDA: DAPTACEL).
Infanrix
Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
Infanrix
GlaxoSmithKline Biologicals
VO_0000064
Toxoid vaccine
Licensed
Intramuscular injection (i.m.)
USA (License #1617 )
The vaccine is an noninfectious, sterile combination of diphtheria and tetanus toxoids and 3 pertussis antigens [inactivated pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (69 kiloDalton outer membrane protein)] adsorbed onto aluminum hydroxide (FDA: Infanrix).
Aluminum Hydroxide
Store INFANRIX refrigerated between 2° and 8°C (36° and 46°F). Do not freeze.
Tetanus toxin is produced by growing Clostridium tetani in a modified Latham medium derived from bovine casein. The toxin is detoxified with formaldehyde, concentrated by ultrafiltration, and purified by precipitation, dialysis, and sterile filtration (FDA: Infanrix).
Intramuscular injection (i.m.)
Diphtheria and tetanus toxoids and 3 pertussis antigens [inactivated pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (69 kiloDalton outer membrane protein)] (FDA: Infanrix).
Infanrix -IPV/Hib
Diphtheria, tetanus, pertussis (acellular component), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed)
Infanrix -IPV/Hib
GlaxoSmithKline
VO_0010722
Subunit vaccine + Inactivated or "killed" vaccine
Licensed
Intramuscular injection (i.m.)
Canada
Products: Proteins + killed virus + conjugate. Other components: Formaldehyde Polysorbate 80, Lactose.
Aluminum Hydroxide
Store in a refrigerator (2°C – 8°C).
Intramuscular injection (i.m.)
Infanrix-hexa
Combined diphtheria and tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis and adsorbed conjugated Haemophilus influenzae type b vaccine
Infanrix-hexa
GlaxoSmithKline
VO_0010719
Subunit vaccine + Inactivated or "killed" vaccine
Licensed
Intramuscular injection (i.m.)
Canada
Products: Proteins + killed viruses + conjugate. Other components: Yeast protein Formaldehyde, Lactose, Polysorbate 20 and 80.
Aluminum phosphate and aluminum hydroxide
Should be stored at 2° to 8°C (35° to 46°F).
Intramuscular injection (i.m.)
Infanrix-IPV
Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed)
Infanrix-IPV
GlaxoSmithKline
VO_0010721
Subunit vaccine + Inactivated or "killed" vaccine
Licensed
Intramuscular injection (i.m.)
Canada
Products: Proteins + killed virus. Other components: Formaldehyde, Polysorbate 80.
Aluminum hydroxide
Store in a refrigerator (2°C - 8°C).
Intramuscular injection (i.m.)
Infanrix/Hib
Combined diphtheria, tetanus, acellular pertussis (DTPa) and Haemophilus influenza type b vaccine
Infanrix/Hib
GlaxoSmithKline
VO_0010720
Subunit vaccine
Licensed
Intramuscular injection (i.m.)
Canada
Products: Proteins + conjugate. Other components: Formaldehyde, Lactose.
Aluminum hydroxide
Refrigerated stored between +2°C and +8°C.
Intramuscular injection (i.m.)
KINRIX
Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
KINRIX
GlaxoSmithKline
VO_0000067
Toxoid vaccine + Subunit vaccine + Inactivated or "killed" vaccine
Licensed
Intramuscular injection (i.m.)
USA
A single dose of KINRIX is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series in children 4 through 6 years of age whose previous DTaP vaccine doses have been with INFANRIX and/or PEDIARIX for the first three doses and INFANRIX for the fourth dose. (FDA: KINRIX)
Aluminum hydroxide
Store refrigerated between 2° and 8°C (36° and 46°F), do not freeze.
The diphtheria toxin is produced by growing Corynebacterium diphtheriae in Fenton medium containing a bovine extract. After, they are detoxified with formaldehyde, concentrated by ultrafiltration, and purified by precipitation, dialysis, and sterile filtration.
Intramuscular injection (i.m.)
Pediacel
Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine and Haemophilus b Conjugate Vaccine (Tetanus Protein – Conjugate)
Pediacel
Sanofi Pasteur Ltd
VO_0010730
Subunit vaccine + Inactivated or "killed" vaccine
Licensed
Intramuscular injection (i.m.)
Canada
Products: Proteins, killed virus + conjugate. Other components: Bovine serum Formaldehyde, Polysorbate 80.
Aluminum phosphate
Store at 2° to 8°C (35° to 46°F).
Intramuscular injection (i.m.)
Pediarix
Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined
Pediarix
GlaxoSmithKline Biologicals
VO_0000082
Toxoid vaccine
Licensed
Intramuscular injection (i.m.)
United States
It contains diphtheria and tetanus toxoids, 3 pertussis antigens (inactivated pertussis toxin [PT] and formaldehyde-treated filamentous hemagglutinin [FHA] and pertactin [69 kiloDalton outer membrane protein]), hepatitis B surface antigen, plus poliovirus Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett) (FDA: Pediarix).
Aluminum hydroxide
The vaccine should be refrigerated between 2º and 8ºC (36º and 46ºF). Do not freeze.
The diphtheria toxin is produced by growing Corynebacterium diphtheriae in Fenton medium containing a bovine extract. The diphtheria, tetanus, and pertussis antigens are individually adsorbed onto aluminum hydroxide then diluted and combined to produce the final formulated vaccine (FDA: Pediarix).
Intramuscular injection (i.m.)
Pentacel
Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine
Pentacel
Sanofi Pasteur Limited
VO_0000084
Subunit vaccine + Inactivated or "killed" vaccine
Licensed
Intramuscular injection (i.m.)
USA (License #1726), Canada
It consists of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus (DTaP-IPV) component and an ActHIB® vaccine component. Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b (FDA: Pentacel).
Aluminum phosphate
Store at 2° to 8°C (35° to 46°F). Do not freeze.
Corynebacterium diphtheriae is grown in modified Mueller’s growth medium. After purification by ammonium sulfate fractionation, the diphtheria toxin is detoxified with formaldehyde and diafiltered (FDA: Pentacel).
Intramuscular injection (i.m.)
Quadracel
Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine
Quadracel
Sanofi Pasteur Ltd
VO_0010736
Subunit vaccine + Inactivated or "killed" vaccine
Licensed
Intramuscular injection (i.m.)
Canada
Aluminum phosphate
Store at 2 to 8C (35 to 46F). Do not freeze.
Intramuscular injection (i.m.)
rBCG-S1PT
VO_0004790
Recombinant vector vaccine
Licensed
Intramuscular injection (i.m.)
Intramuscular injection (i.m.)
BCG vaccine with S1 subunit of detoxified B. pertussis toxin; PT-9K/129G (Nascimento et al., 2008).
Mice were immunized with 50μl of one-tenth dose of an adult mouse of DTP at day 5 (or day 12 as specified) or 10^5 CFU of BCG or rBCG-S1PT on day 5 according to different regimens (Nascimento et al., 2008).
VO_0003057
A single dose of rBCG-S1PT at day 5 led to a 100% survival of mice, and even at an extremely high challenge dose (300 times the lethal adult dose) rBCG-S1PT still induced 50% survival of neonate-immunized mice. Mice immunized with BCG alone experienced a protective effect of 80%, however at a higher challenge dose, this effect was reduced to 50%. Mice immunized with DTP showed no protection (Nascimento et al., 2008).
Mice were subjected to intracerebral inoculation with a lethal dose of B. pertussis with approximately 3 x 10^4, 3 x 10^5, or 9 x 10^5 CFU (in 30μl) on day 21 after birth.
S. gordonii-PT
VO_0004670
Recombinant vector vaccine
Research
Intramuscular injection (i.m.)
(Lee et al., 1999)
Intramuscular injection (i.m.)
Tripacel
Pertussis Vaccine-Acellular, Combined with Diphtheria and Tetanus Toxoids (Adsorbed)
Tripacel
Sanofi Pasteur Ltd
VO_0010742
Subunit vaccine
Licensed
Intramuscular injection (i.m.)
Canada
Aluminum phospate
Store at at 2° to 8°C.
Intramuscular injection (i.m.)
Tripedia
Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
Tripedia
Sanofi Pasteur, Inc.
VO_0000112
Toxoid vaccine
Licensed
Intramuscular injection (i.m.)
USA (FDA License #1725)
Tripedia vaccine combines diptheria and tetanus toxoids with purified pertussis antigens. It consists of 3 doses administered at intervals of 4-8 weeks (FDA: Tripedia).
aluminum potassium sulfate
Store between 2 and 8 degrees Celsius. DO NOT FREEZE.
Intramuscular injection (i.m.)
VC-TetC/Tcf
VC expressing B. pertussis TetC/Tcf
VO_0004781
Recombinant vector vaccine
Research
intranasal immunization
An attenuated strain of Vibrio cholerae was used as a carrier for the expression of heterologous antigens such as fragment C from tetanus toxin (TetC) and tracheal colonization factor from Bordetella pertussis (Tcf) (Chen et al., 1998).
intranasal immunization
Recombinant protein preparation
An attenuated strain of Vibrio cholerae was used as a carrier for the expression of heterologous antigens such as fragment C from tetanus toxin (TetC) and tracheal colonization factor from Bordetella pertussis (Tcf) (Chen et al., 1998).
VO_0000287
Mice vaccinated with IEM101 expressing Tcf experienced significant reduction in bacterial colonization of their tracheas (Chen et al., 1998).
Mice were challenged with wild-type B. pertussis (Chen et al., 1998).
aroA
144037
CDD:179423
CDD:30129
520
?
442
3-phosphoshikimate 1-carboxyvinyltransferase; Provisional
>gi|144037|gb|AAA22968.1| 5-enolpyruvylshikimate-3-phosphate synthase (EC 2.5.1.19) [Bordetella pertussis]
MSGLAYLDLPAARLARGEVALPGSKSISNRVLLLAALAEGSTEITGLLDSDDTRVMLAALRQLGVSVGEV
ADGCVTIEGVARFPTEQAELFLGNAGTAFRPLTAALALMGGDYRLSGVPRMHERPIGDLVDALRQFGAGI
EYLGQAGYPPLRIGGGSIRVDGPVRVEGSVSSQFLTALLMAAPVLARRSGQDITIEVVGELISKPYIEIT
LNLMARFGVSVRRDGWRAFTIARDAVYRGPGRMAIEGDASTASYFLALGAIGGGPVRVTGVGEDSIQGDV
AFAATLAAMGADVRYGPGWIETRGVRVAEGGRLKAFDADFNLIPDAAMTAATLALYADGPCRLRNIGSWR
VKETDRIHAMHTELEKLGAGVQSGADWLEVAPPEPGGWRDAHIGTWDDHRMAMCFLLAAFGPAAVRILDP
GCVSKTFPDYFDVYAGLLAARD
Virmugen
An aroA mutant is highly attenuated in mice and induces significant protection from challenge with wild type B. pertussis [Ref1660:Roberts et al., 1990].
brkA
Bordetella pertussis
VO_0011036
562026
CDD:332715
CDD:238653
CDD:273608
520
?
BrkA
7.12
96022.08
1066
Domain of Unknown Function (DUF1522); cl27894
>AAA51646.1 BrkA [Bordetella pertussis]
MYLDRFRQCPSSLQIPRSAWRLHALAAALALAGMARLAPAAAQAPQPPVAGAPHAQDAGQEGEFDHRDNT
LIAVFDDGVGINLDDDPDELGETAPPTLKDIHISVEHKNPMSKPAIGVRVSGAGRALTLAGSTIDATEGG
IPAVVRRGGTLELDGVTVAGGEGMEPMTVSDAGSRLSVRGGVLGGEAPGVGLVRAAQGGQASIIDATLQS
ILGPALIADGGSISVAGGSIDMDMGPGFPPPPPPLPGAPLAAHPPLDRVAAVHAGQDGKVTLREVALRAH
GPQATGVYAYMPGSEITLQGGTVSVQGDDGAGVVAGAGLLDALPPGGTVRLDGTTVSTDGANTDAVLVRG
DAARAEVVNTVLRTAKSLAAGVSAQHGGRVTLRQTRIETAGAGAEGISVLGFEPQSGSGPASVDMQGGSI
TTTGNRAAGIALTHGSARLEGVAVRAEGSGSSAAQLANGTLVVSAGSLASAQSGAISVTDTPLKLMPGAL
ASSTVSVRLTDGATAQGGNGVFLQQHSTIPVAVALESGALARGDIVADGNKPLDAGISLSVASGAAWHGA
TQVLQSATLGKGGTWVVNADSRVQDMSMRGGRVEFQAPAPEASYKTLTLQTLDGNGVFVLNTNVAAGQND
QLRVTGRADGQHRVLVRNAGGEADSRGARLGLVHTQGQGNATFRLANVGKAVDLGTWRYSLAEDPKTHVW
SLQRAGQALSGAANAAVNAADLSSIALAESNALDKRLGELRLRADAGGPWARTFSERQQISNRHARAYDQ
TVSGLEIGLDRGWSASGGRWYAGGLLGYTYADRTYPGDGGGKVKGLHVGGYAAYVGDGGYYLDTVLRLGR
YDQQYNIAGTDGGRVTADYRTSGAAWSLEGGRRFELPNDWFAEPQAEVMLWRTSGKRYRASNGLRVKVDA
NTATLGRLGLRFGRRIALAGGNIVQPYARLGWTQEFKSTGDVRTNGIGHAGAGRHGRVELGAGVDAALGK
GHNLYASYEYAAGDRINIPWSFHAGYRYSF
Protective antigen
A soluble fraction obtained from Bordetella pertussis was evaluated as adjuvant for the pertussis component of the Diphtheria-Pertussis-Tetanus (DPT) vaccine. High levels of antibodies were induced, and a 78% protection rate of mice challenged with live B. pertussis was observed. Two proteins were identified as the 73 kDa N-terminal alpha-domain of BrkA autotransporter protein and the Cpn60/60 kDa chaperonin. Both stimulated antibodies against pertussis and induced a 42% protection rate against the challenge [Ref1024:Cainelli et al., 2007].
cpn60
Bordetella pertussis
VO_0011035
968920
CDD:234573
CDD:239460
520
?
Cpn60 (GroEL)
4.81
52145.9
605
chaperonin GroEL; Reviewed; PRK00013
>AAA74967.1 Cpn60 (GroEL) [Bordetella pertussis]
MAAKQVLFADEARVRIVRGVNVLANAVKTTLGPKGRNVVLERSFGAPTVTKDGVSVAKEIELKDKFENIG
AQLVKDVASKTSDNAGDGTTTATVLAQAVVQEGLKYVAAGFNPIDLKRGIDKAVAAAVEELKKLSKPVTT
SKEIAQVGSISANSDASIGQIIADAMDKVGKEGVITVEDGKSLENELDVVEGMQFDRGYLSPYFINSPEK
QVAALDDPYVLIYDKKVSNIRDLLPVLEQVAKSSRPLLIIAEDVEGEALATLVVNNIRGILKTTAVKAPG
FGDRRKAMLEDIAILTGGTVISEETGMSLEKATLQDLGQAKRIEVAKENTTIIDGAGDGKSIEARVKQIR
AQIEEATSDYDREKLQERVAKLAGGVAVIRVGAATEVEMKEKKARVEDALHATRAAVEEGVVPGGGVALL
RAKQAITGLKGDTADQNAGIKLILRAVEEPLRTIVTNAGDEASVVVNTVLNGKGNYGYNAATGEYGDLVE
QGVLDPTKVTRTALQNAASVASLLLTAEAAVVELMENKPAAAPAMPGGMGGMGGMDF
Protective antigen
A soluble fraction obtained from Bordetella pertussis was evaluated as adjuvant for the pertussis component of the Diphtheria-Pertussis-Tetanus (DPT) vaccine. High levels of antibodies were induced, and a 78% protection rate of mice challenged with live B. pertussis was observed. Two proteins were identified as the 73 kDa N-terminal alpha-domain of BrkA autotransporter protein and the Cpn60/60 kDa chaperonin. Both stimulated antibodies against pertussis and induced a 42% protection rate against the challenge [Ref1024:Cainelli et al., 2007].
CyaA
Bordetella pertussis
VO_0011031
580668
2COL
CDD:281494
CDD:280531
CDD:225483
CDD:305016
520
?
adenylate cyclase
4.36
164358.59
1785
Anthrax toxin LF subunit; pfam03497
>CAA01202.1 adenylate cyclase [Bordetella pertussis]
MQQSHQAGYANAADRESGIPAAVLDGIKAVAKEKNATLMFRLVNPHSTSLIAEGVATKGLGVHAKSSDWG
LQAGYIPVNPNLSKLFGRAPEVIARADNDVNSSLAHGHTAVDLTLSKERLDYLRQAGLVTGMADGVVASN
HAGYEQFEFRVKETSDGRYAVQYRRKGGDDFEAVKVIGNAAGIPLTADIDMFAIMPHLSNFRDSARSSVT
SGDSVTDYLARTRRAASEATGGLDRERIDLLWKIARAGARSAVGTEARRQFRYDGDMNIGVITDFELEVR
NALNRRAHAVGAQDVVQHGTEQNNPFPEADEKIFVVSATGESQMLTRGQLKEYIGQQRGEGYVFYENRAY
GVAGKSLFDDGLGAAPGVPSGRSKFSPDVLETVPASPGLRRPSLGAVERQDSGYDSLDGVGSRSFSLGEV
SDMAAVEAAELEMTRQVLHAGARQDDAEPGVSGASAHWGQRALQGAQAVAAAQRLVHAIALMTQFGRAGS
TNTPQEAASLSAAVFGLGEASSAVAETVSGFFRGSSRWAGGFGVAGGAMALGGGIAAAVGAGMSLTDDAP
AGQKAAAGAEIALQLTGGTVELASSIALALAAARGVTSGLQVAGASAGAAAGALAAALSPMEIYGLVQQS
HYADQLDKLAQESSAYGYEGDALLAQLYRDKTAAEGAVAGVSAVLSTVGAAVSIAAAASVVGAPVAVVTS
LLTGALNGILRGVQQPIIEKLANDYARKIDELGGPQAYFEKNLQARHEQLANSDGLRKMLADLQAGWNAS
SVIGVQTTEISKSALELAAITGNADNLKSVDVFVDRFVQGERVAGQPVVLDVAAGGIDIASRKGERPALT
FITPLAAPGEEQRRRTKTGKSEFTTFVEIVGKQDRWRIRDGAADTTIDLAKVVSQLVDANGVLKHSIKLD
VIGGDGDDVVLANASRIHYDGGAGTNTVSYAALGRQDSITVSADGERFNVRKQLNNANVYREGVATQTTA
YGKRTENVQYRHVELARVGQVVEVDTLEHVQHIIGGAGNDSITGNAHDNFLAGGSGDDRLDGGAGNDTLV
GGEGQNTVIGGAGDDVFLQDLGVWSNQLDGGAGVDTVKYNVHQPSEERLERMGDTGIHADLQKGTVEKWP
ALNLFSVDHVKNIENLHGSRLNDRIAGDDQDNELWGHDGNDTIRGRGGDDILRGGLGLDTLYGEDGNDIF
LQDDETVSDDIDGGAGLDTVDYSAMIHPGRIVAPHEYGFGIEADLSREWVRKASALGVDYYDNVRNVENV
IGTSMKDVLIGDAQANTLMGQGGDDTVRGGDGDDLLFGGDGNDMLYGDAGNDTLYGGLGDDTLEGGAGND
WFGQTQAREHDVLRGGDGVDTVDYSQTGAHAGIAAGRIGLGILADLGAGRVDKLGEAGSSAYDTVSGIEN
VVGTELADRITGDAQANVLRGAGGADVLAGGEGDDVLLGGDGDDQLSGDAGRDRLYGEAGDDWFFQDAAN
AGNLLDGGDGRDTVDFSGPGRGLDAGAKGVFLSLGKGFASLMDEPETSNVLRNIENAVGSARDDVLIGDA
GANVLNGLAGNDVLSGGAGDDVLLGDEGSDLLSGDAGNDDLFGGQGDDTYLFGVGYGHDTIYESGGGHDT
IRINAGADQLWFARQGNDLEIRILGTDDALTVHDWYRDADHRVEIIHAANQAVDQAGIEKLVEAMAQYPD
PGAAAAAPPAARVPDTLMQSLAVNWR
Protective antigen
A study demonstrated that passive immunization with specific anti-B. pertussis adenylate cyclase antibodies or active immunization with purified B. pertussis secreted adenylate cyclase (cyaA) protect mice against a lethal respiratory challenge with B. pertussis or B. parapertussis. Results suggest that adenylate cyclase might be the primary cytotoxin responsible for mouse pulmonary lesions during respiratory tract infection with B. pertussis or with the related species B. parapertussis and is a protective antigen of B. pertussis [Ref1019:Guiso et al., 1989].
dnt
Bordetella pertussis Tohama I
2666936
33594321
BP3439
BX640421
NP_881965
257313
3647083
3651477
+
dermonecrotic toxin
6.49
150126.42
1464
Previously sequenced as Bordetella pertussis dermonecrotic toxin Dnt TR:Q45336 (EMBL:U10527) (1451 aa) fasta scores: E(): 0, 100% id in 1451 aa. Almost identical to Bordetella bronchiseptica dermonecrotizing toxin TR:Q9S5D5 (EMBL:AB020025) (1464 aa) fasta scores: E(): 0, 98.97% id in 1464 aa
>gi|33591275:3647083-3651477 Bordetella pertussis Tohama I, complete genome
CGTGGATAAAGATGAATCGGCATTGCGGCAACTTGTCGACATGGCGCTTGTAGGCTACGACGGCGTGGTG
GAAGAGTTGCTGGCGCTGCCCTCGGAAGAGTCCGGGGATCTTGCGGGTGGACGGGCCAAACGAGAGAAGG
CCGAATTCGCGCTGTTTAGCGAAGCGCCCAACGGGGATGAACCCATCGGCCAGGATGCTCGTACATGGTT
CTATTTTCCCAAGTACCGCCCGGTGGCGGTTTCCAATTTGAAGAAAATGCAGGTGGCGATTCGTGCTCGT
CTCGAGCCTGAGTCATTGATCCTGCAGTGGTTGATCGCACTCGATGTCTATCTCGGCGTGTTGATCGCCG
CCTTGTCCCGCACTGTGATCAGCGACCTGGTATTCGAGTATGTCAAGGCGCGCTACGAGATCTACTACCT
ACTGAATCGCGTGCCGCATCCGCTGGCGACGGCGTACCTCAAGCGCCGCCGCCAGCGTCCGGTGGATCGT
TCGGGACGTCTGGGCTCGGTGTTCGAACACCCGCTATGGTTCGCCTACGACGAATTGGCCGGCACCGTCG
ATCTGGATGCCGACATCTACGAGCAGGCGCTCGCCGAAAGCATCGAACGCCGCATGGACGGAGAGCCGGA
CGACGGCAGTCTGGATACCGCCGAACACGACGTATGGCGTTTGTGCCGCGACGGCATCAATCGGGGCGAG
CAGGCGATTTTCCAGGCATCCGGCCCATATGGCGTGGTCGCGGATGCAGGGTATATGCGCACCGTTGCCG
ATCTGGCGTATGCCGATGCATTGGCGGATTGCCTGCATGCCCAACTGCGCATCCGGGCGCAAGGCTCGGT
CGATAGCCCGGGAGACGAGATGCCACGCAAACTTGATGCGTGGGAAATCGCCAAGTTTCATCTGGCCGCG
ACCCAGCAGGCGCGGGTTGATCTGCTCGAGGCGGCGTTCGCGCTCGACTACGCCGCCTTGCGCGATGTGC
GCGTCTACGGCGATTACCGCAATGCGCTGGCTCTTCGGTTCATCAAGCGCGAGGCCTTGCGGTTGCTGGG
GGCGCGGCGCGGCAACGCCTCTACGATGCCGGCGGTTGCGGCTGGCGAGTACGACGAAATCGTGGCCAGT
GGAGCAGCCAATGACGCGGCTTATGTATCCATGGCCGCCGCGTTGATCGCGGGCGTGCTCTGCGATCTCG
AGAGCGCGCAGCGCACGTTGCCCGTCGTATTGGCCAGGTTTCGGCCCCTTGGCGTGCTTGCGCGATTCAG
AAGGCTGGAGCAGGAAACCGCGGGCATGCTGCTTGGCGACCAGGAGCCGGAGCCTCGGGGCTTCATCAGT
TTTACCGATTTTCGCGATAGCGACGCGTTCGCCAGCTACGCGGAGTATGCGGCCCAGTTCAACGACTATA
TCGATCAATACAGCATACTCGAGGCGCAGCGGCTGGCGCGGATTCTGGCCCTGGGCTCGCGGATGACGGT
CGATCAATGGTGCCTTCCCCTGCAGAAAGTACGGCACTACAAGGTGCTGACATCGCAGCCAGGGCTGATC
GCGCGTGGAATCGAAAATCACAACAGGGGCATTGAATATTGCCTGGGGCGGCCGCCGCTGACCGATCTGC
CGGGTCTTTTCACCATGTTCCAGCTCCATGATTCCAGCTGGCTGTTGGTATCGAACATCAACGGTGAGCT
TTGGTCTGATGTCCTTGCGAACGCTGAGGTGATGCAGAATCCTACGCTGGCCGCCCTTGCCGAGCCGCAA
GGCCGCTTTCGAACCGGCCGTCGAACGGGCGGGTGGTTTCTCGGCGGCCCCGCGACTGAAGGGCCAAGTC
TGCGCGACAACTACCTCCTCAAATTGAGGCAGAGCAATCCGGGGCTGGATGTCAAGAAATGCTGGTATTT
CGGGTATCGGCAAGAGTACAGGCTGCCCGCAGGCGCGCTGGGTGTGCCGCTATTCGCTGTTTCCGTTGCC
CTGAGGCACAGTCTGGACGACCTCGCGGCGCACGCGAAGTCCGCTTTGTACAAACCCAGCGAATGGCAGA
AGTTCGCCTTCTGGATCGTGCCGTTCTACCGGGAAATATTCTTTTCGACCCAGGATCGTTCCTATCGGGT
CGATGTGGGGAGCATCGTCTTTGATTCGATTTCCTTGCTTGCCTCGGTGTTCAGCATAGGAGGGAAGTTG
GGCAGTTTCACCCGTACCCAGTATGGCAACCTGCGCAATTTCGTGGTGCGGCAACGCATCGCGGGGTTGA
GCGGGCAGCGCTTGTGGCGTTCGGTGCTCAAGGAGCTTCCGGCATTGATCGGAGCCAGCGGGTTGCGCCT
GTCGCGTTCGCTGCTCGTCGATCTGTATGAGATCTTCGAGCCCGTGCCTATCCGTCGGCTTGTCGCGGGA
TTCGTGAGCGCCACTACGGTCGGCGGGCGTAACCAGGCCTTCCTGCGGCAGGCATTCTCCGCTGCCAGTT
CCTCGGCCGGGCGCACGGGGGGCCAATTGGCAAGCGAATGGCGGATGGCCGGCGTGGACGCCACCGGTTT
GGTCGAGTCCACGTCGGGCGGCAGGTTTGAGGGCATCTACACGCGCGGCTTGGGACCGTTGAGCGAGTGC
ACCGAGCACTTCATCGTCGAATCCGGGAATGCCTACAGAGTCATCTGGGATGCATACACGCATGGTTGGC
GCGTGGTCAATGGGCGTTTGCCGCCGAGGCTGACCTATACCGTTCCGGTTCGGCTGAACGGGCAAGGCCA
CTGGGAGACGCATCTGGATGTCCCTGGCCGGGGTGGGGCGCCGGAAATCTTCGGACGCATCCGCACGCGT
AATCTGGTCGCCCTTGCCGCCGAGCAGGCCGCGCCGATGCGCCGCCTGCTCAACCAGGCGAGGCGTGTGG
CGCTCAGGCATATCGATACCTGCAGGAGCAGGCTTGCGTTGCCGCGCGCTGAATCCGATATGGACGCGGC
GATCCGGATTTTCTTCGGAGAGCCGGACGCCGGCCTTCGCCAGCGCATCGGGCGACGCCTGCAGGAGGTC
AGGGCCTATATCGGCGATCTGAGTCCGGTCAATGACGTGCTGTACCGGGCGGGATATGACCTCGACGATG
TCGCAACGCTGTTTAACGCAGTGGACCGGAACACGTCGCTGGGCAGGCAGGCTCGGATGGAGTTGTATCT
GGATGCCATTGTCGATTTGCATGCCAGGCTCGGCTATGAAAATGCGCGTTTTGTCGACCTGATGGCGTTC
CACCTGCTCAGCCTGGGCCATGCCGCGACGGCCAGTGAGGTCGTGGAGGCCGTTTCGCCCCGGCTGCTGG
GCAATGTGTTCGATATCTCGAACGTCGCCCAGCTCGAACGCGGTATCGGGAATCCCGCCAGCACCGGTCT
TTTCGTCATGCTGGGCGCCTATTCGGAATCGTCGCCCGCGATATTCCAGTCGTTCGTGAACGATATATTT
CCCGCATGGCGACAGGCTTCCGGCGGGGGGCCGCTGGTATGGAACTTCGGTCCTGCCGCCATCAGCCCGA
CGCGCCTGGATTACGCAAATACCGATATCGGATTGCTCAACCATGGGGATATTTCCCCGCTGCGCGCCAG
GCCGCCATTGGGCGGCAGGCGCGACATCGATCTTCCTCCGGGGCTGGATATTTCGTTCGTGCGTTACGAC
CGCCCGGTGCGCATGTCCGCGCCGCGTGCGCTCGACGCCAGCGTCTTCAGGCCGGTCGACGGGCCTGTCC
ATGGCTATATTCAATCGTGGACGGGGGCTGAGATCGAATATGCGTACGGCGCGCCCGCAGCGGCACGCGA
GGTCATGCTGACCGACAATGTGCGGATCATCAGCATCGAGAACGGCGATGAAGGGGCGATCGGGGTGCGC
GTGAGGCTCGACACTGTTCCCGTCGCGACGCCGCTCATCCTGACTGGCGGCTCCTTGAGCGGGTGCACGA
CGATGGTTGGGGTCAAGGAGGGCTACCTGGCCTTCTACCACACTGGCAAGTCGACCGAACTCGGGGATTG
GGCGACTGCGCGCGAAGGCGTACAGGCGCTTTACCAGGCCCATTTGGCGATGGGGTACGCGCCGATCTCA
ATCCCGGCGCCGATGCGCAATGACGACTTGGTCAGCATCGCCGCGACCTACGACCGGGCGGTCATTGCCT
ATCTGGGCAAGGATGTGCCGGGAGGCGGCAGTACGCGCATAACGCGTCACGATGAGGGGGCGGGCAGTGT
GGTTTCGTTCGACTACAACGCAGCAGTCCAGGCGTCGGCCGTTCCCCGCCTCGGCCAGGTATACGTTCTG
ATTTCCAACGACGGACAAGGGGCGCGAGCCGTCCTGCTGGCGGAGGATCTGGCCTGGGCAGGCAGCGGCA
GTGCCTTGGATGTGTTGAACGAACGATTGGTGACGTTGTTTCCGGCGCCGGTCTG
>gi|33594321|ref|NP_881965.1| dermonecrotic toxin [Bordetella pertussis Tohama I]
MDKDESALRQLVDMALVGYDGVVEELLALPSEESGDLAGGRAKREKAEFALFSEAPNGDEPIGQDARTWF
YFPKYRPVAVSNLKKMQVAIRARLEPESLILQWLIALDVYLGVLIAALSRTVISDLVFEYVKARYEIYYL
LNRVPHPLATAYLKRRRQRPVDRSGRLGSVFEHPLWFAYDELAGTVDLDADIYEQALAESIERRMDGEPD
DGSLDTAEHDVWRLCRDGINRGEQAIFQASGPYGVVADAGYMRTVADLAYADALADCLHAQLRIRAQGSV
DSPGDEMPRKLDAWEIAKFHLAATQQARVDLLEAAFALDYAALRDVRVYGDYRNALALRFIKREALRLLG
ARRGNASTMPAVAAGEYDEIVASGAANDAAYVSMAAALIAGVLCDLESAQRTLPVVLARFRPLGVLARFR
RLEQETAGMLLGDQEPEPRGFISFTDFRDSDAFASYAEYAAQFNDYIDQYSILEAQRLARILALGSRMTV
DQWCLPLQKVRHYKVLTSQPGLIARGIENHNRGIEYCLGRPPLTDLPGLFTMFQLHDSSWLLVSNINGEL
WSDVLANAEVMQNPTLAALAEPQGRFRTGRRTGGWFLGGPATEGPSLRDNYLLKLRQSNPGLDVKKCWYF
GYRQEYRLPAGALGVPLFAVSVALRHSLDDLAAHAKSALYKPSEWQKFAFWIVPFYREIFFSTQDRSYRV
DVGSIVFDSISLLASVFSIGGKLGSFTRTQYGNLRNFVVRQRIAGLSGQRLWRSVLKELPALIGASGLRL
SRSLLVDLYEIFEPVPIRRLVAGFVSATTVGGRNQAFLRQAFSAASSSAGRTGGQLASEWRMAGVDATGL
VESTSGGRFEGIYTRGLGPLSECTEHFIVESGNAYRVIWDAYTHGWRVVNGRLPPRLTYTVPVRLNGQGH
WETHLDVPGRGGAPEIFGRIRTRNLVALAAEQAAPMRRLLNQARRVALRHIDTCRSRLALPRAESDMDAA
IRIFFGEPDAGLRQRIGRRLQEVRAYIGDLSPVNDVLYRAGYDLDDVATLFNAVDRNTSLGRQARMELYL
DAIVDLHARLGYENARFVDLMAFHLLSLGHAATASEVVEAVSPRLLGNVFDISNVAQLERGIGNPASTGL
FVMLGAYSESSPAIFQSFVNDIFPAWRQASGGGPLVWNFGPAAISPTRLDYANTDIGLLNHGDISPLRAR
PPLGGRRDIDLPPGLDISFVRYDRPVRMSAPRALDASVFRPVDGPVHGYIQSWTGAEIEYAYGAPAAARE
VMLTDNVRIISIENGDEGAIGVRVRLDTVPVATPLILTGGSLSGCTTMVGVKEGYLAFYHTGKSTELGDW
ATAREGVQALYQAHLAMGYAPISIPAPMRNDDLVSIAATYDRAVIAYLGKDVPGGGSTRITRHDEGAGSV
VSFDYNAAVQASAVPRLGQVYVLISNDGQGARAVLLAEDLAWAGSGSALDVLNERLVTLFPAPV
Virmugen
A live attenuated B. pertussis vaccine strain BPZE1 that protects mice upon a single intranasal administration was developed by deleting dnt gene [Ref1805:Feunou et al., 2008].
fhaB
Bordetella pertussis
VO_0011030
3980256
1RWR
CDD:289765
CDD:283510
CDD:293785
CDD:290071
CDD:292650
GOA:Q45365
InterPro:IPR008619
InterPro:IPR008638
InterPro:IPR010069
InterPro:IPR011050
InterPro:IPR011102
InterPro:IPR012334
UniProtKB/TrEMBL:Q45365
520
?
filamentous hemagglutinin
9.21
332849.05
3704
Extended Signal Peptide of Type V secretion system; pfam13018
>CAA36409.1 filamentous hemagglutinin [Bordetella pertussis]
MNTNLYRLVFSHVRGMLVPVSEHCTVGNTFCGRTRGQARSGARATSLSVAPNALAWALMLACTGLPLVTH
AQGLVPQGQTQVLQGGNKVPVVNIADPNSGGVSHNKFQQFNVANPGVVFNNGLTDGVSRIGGALTKNPNL
TRQASAILAEVTDTSPSRLAGTLEVYGKGADLIIANPNGISVNGLSTLNASNLTLTTGRPSVNGGRIGLD
VQQGTVTIERGGVNATGLGYFDVVARLVKLQGAVSSKQGKPLADIAVVAGANRYDHATRRATPIAAGARG
AAAGAYAIDGTAAGAMYGKHITLVSSDSGLGVRQLGSLSSPSAITVSSQGEIALGDATVQRGPLSLKGAG
VVSAGKLASGGGAVNVAGGGAVKIASASSVGNLAVQGGGKVQATLLNAGGTLLVSGRQAVQLGAASSRQA
LSVNAGGALKADKLSATRRVDVDGKQAVALGSASSNALSVRAGGALKAGKLSATGRLDVDGKQAVTLGSV
ASDGALSVSAGGNLRANELVSSAQLEVRGQREVALDDASSARGMTVVAAGALAARNLQSKGAIGVQGGEA
VSVANANSDAELRVRGRGQVDLHDLSAARGADISGEGRVNIGRARSDSDVKVSAHGALSIDSMTALGAIG
VQAGGSVSAKDMRSRGAVTVSGGGAVNLGDVQSDGQVRATSAGAMTVRDVAAAADLALQAGDALQAGFLK
SAGAMTVNGRDAVRLDGAHAGGQLRVSSDGQAALGSLAAKGELTVSAARAATVAELKSLDNISVTGGERV
SVQSVNSASRVAISAHGALDVGKVSAKSGIGLEGWGAVGADSLGSDGAISVSGRDAVRVDQARSLADISL
GAEGGATLGAVEAAGSIDVRGGSTVAANSLHANRDVRVSGKDAVRVTAATSGGGLHVSSGRQLDLGAVQA
RGALALDGGAGVALQSAKASGTLHVQGGEHLDLGTLAAVGAVDVNGTGDVRVAKLVSDAGADLQAGRSMT
LGIVDTTGDLQARAQQKLELGSVKSDGGLQAAAGGALSLAAAEVAGALELSGQGVTVDRASASRARIDST
GSVGIGALKAGAVEAASPRRARRALRQDFFTPGSVVVRAQGNVTVGRGDPHQGVLAQGDIIMDAKGGTLL
LRNDALTENGTVTISADSAVLEHSTIESKISQSVLAAKGDKGKPAVSVKVAKKLFLNGTLRAVNDNNETM
SGRQIDVVDGRPQITDAVTGEARKDESVVSDAALVADGGPIVVEAGELVSHAGGIGNGRNKENGASVTVR
TTGNLVNKGYISAGKQGVLEVGGALTNEFLVGSDGTQRIEAQRIENRGTFQSQAPAGTAGALVVKAAEAI
VHDGVMATKGEMQIAGKGGGSPTVTAGAKATTSANKLSVDVASWDNAGSLDIKKGGAQVTVAGRYAEHGE
VSIQGDYTVSADAIALAAQVTQRGGAANLTSRHDTRFSNKIRLMGPLQVNAGGPVSNTGNLKVREGVTVT
AASFDNETGAEVMAKSATLTTSGAARNAGKMQVKEAATIVAASVSNPGTFTAGKDITVTSRGGFDNEGKM
ESNKDIVIKTEQFSNGRVLDAKHDLTVTASGQADNRGSLKAGHDFTVQAQRIDNSGTMAAGHDATLKAPH
LRNTGQVVAGHDIHIINSAKLENTGRVDARNDIALDVADFTNTGSLYAEHDATLTLAQGTQRDLVVDQDH
ILPVAEGTLRVKAKSLTTEIETGNPGSLIAEVQENIDNKQAIVVGKDLTLSSAHGNVANEANALLWAAGE
LTVKAQNITNKRAALIEAGGNARLTAAVALLNKLGRIRAGEDMHLDAPRIENTAKLSGEVQRKGVQDVGG
GEHGRWSGIGYVNYWLRAGNGKKAGTIAAPWYGGDLTAEQSLIEVGKDLYLNAGARKDEHRHLLNEGVIQ
AGGHGHIGGDVDNRSVVRTVSAMEYFKTPLPVSLTALDNRAGLSPATWNFQSTYELLDYLLDQNRYEYIW
GLYPTYTEWSVNTLKNLDLGYQAKPAPTAPPMPKAPELDLRGHTLESAEGRKIFGEYKKLQGEYEKAKMA
VQAVEAYGEATRRVHDQLGQRYGKALGGMDAETKEVDGIIQEFAADLRTVYAKQADQATIDAETDKVAQR
YKSQIDAVRLQAIQPGRVTLAKALSAALGADWRALGHSQLMQRWKDFKAGKRGAEIAFYPKEQTVLAAGA
GLTLSNGAIHNGENAAQNRGRPEGLKIGAHSATSVSGSFDALRDVGLEKRLDIDDALAAVLVNPHIFTRI
GAAQTSLADGAAGPALARQARQAPETDGMVDARGLGSADALASLASLDAAQGLEVSGRRNAQVADAGLAG
PSAVAAPAVGAADVGVEPVTGDQVDQPVVAVGLEQPVATVRVAPPAVALPRPLFETRIKFIDQSKFYGSR
YFFEQIGYKPDRAARVAGDNYFDTTLVREQVRRALGGYESRLPVRGVALVAKLMDSAGTVGKALGLKVGV
APTAQQLKQADRDFVWYVDTVIDGQKVLAPRLYLTEATRQGITDQYAGGGALIASGGDVTVNTDGHDVSS
VNGLIQGRSVKVDAGKGKVVVADSKGAGGGIEADDEVDVSGRDIGIEGGKLRGKDVRLKADTVKVATSMR
YDDKGRLAARGDGALDAQGGQLHIEAKRLETAGATLKGGKVKLDVDDVKLGGVYEAGSSYENKSSTPLGS
LFAILSSTTETNQSAHANHYGTRIEAGTLEGKMQNLEIEGGSVDAAHTDLSVARDARFKAAADFAHAEHE
KDVRQLSLGAKVGAGGYEAGFSLGSESGLEAHAGRGMTAGAEVKVGYRASHEQSSETEKSYRNANLNFGG
GSVEAGNVLDIGGADINRNRYGGAAKGNAGTEEALRMRAKKVESTKYVSEQTSQSSGWSVEVASTASARS
SLLTAATRLGDSVAQNVEDGREIRGELMAAQVAAEATQLVTADTAAVALSAGISADFDSSHSRSTSQNTQ
YLGGNLSIEATEGDATLVGAKFGGGDQVSLKAAKSVNLMAAESTFESYSESHNFHASADANLGANAVQGA
VGLGLTAGMGTSHQITNETGKTYAGTSVDAANVSIDAGKDLNLSGSRVRGKHVVLDVEGDINATSKQDER
NYNSSGGGWDASAGVAIQNRTLVAPVGSAGFNFNTEHDNSRLTNDGAAGVVASDGLTGHVKGDANLTGAT
IADLSGKGNLKVDGAVNAQNLKDYRDKDGGSGGLNVGISSTTLAPTVGVAFGRVAGEDYQAEQRATIDVG
QTKDPARLQVGGGVKGTLNQDAAQATVVQRNKHWAGGGSEFSVAGKSLKKKNQVRPVETPTPDVVDGPPS
RPTTPPASPQPIRATVEVSSPPPVSVATVEVVPRPKVETGSAASASAGGAQVVPVTPPKVEVAKVEVVPR
PKVETAQPLPPRPVVAEKVTTPAVQPQLAKVETVQPVKPETTKPLPKPLPVAKVTKAPPPVVETAQPLPP
VKPQKATPGPVAEVGKATVTTVQVQSAPPKPAPVAKQPAPAPKPKPKPKPKAERPKPGKTTPLSGRHVVQ
QQVQVLQRQASDINNTKSLPGGKLPKPVTVKLTDENGKPQTYTINRREDLMKLNGKVLSTKTTLGLEQTF
RLRVEDIGGKNYRVFYETNK
Protective antigen
A combination of the 69-kDa outer membrane protein and filamentous hemagglutinin (fhaB), both isolated from lymphocytosis promoting factor (LPF; pertussis toxin) minus mutants of Bordetella pertussis, is protective in the mouse intracerebral challenge potency (Kendrick) test [Ref1017:Novotny et al., 1991].
Prn
Bordetella pertussis Tohama I
VO_0011033
2664290
33592195
BP1054
BX470248
NP_879839
257313
1098090
1100822
+
pertactin autotransporter
9.61
86606.91
910
Identical to the previously sequenced Bordetella pertussis pertactin precursor Prn or Omp69A SW:PERT_BORPE (P14283) (910 aa) fasta scores: E(): 0, 100% id in 910 aa, and to Bordetella bronchiseptica pertactin precursor Prn SW:PERT_BORBR (Q03035) (911 aa) fasta scores: E(): 1.4e-160, 91.31% id in 921 aa
>NC_002929.2:1098090-1100822 Bordetella pertussis Tohama I chromosome, complete genome
AATGAACATGTCTCTGTCACGCATTGTCAAGGCGGCGCCCCTGCGCCGCACCACGCTGGCCATGGCGCTG
GGCGCGCTGGGCGCCGCCCCGGCGGCGCATGCCGACTGGAACAACCAGTCCATCGTCAAGACCGGTGAGC
GCCAGCATGGCATCCATATCCAGGGCTCCGACCCGGGCGGCGTACGGACCGCCAGCGGAACCACCATCAA
GGTAAGCGGCCGTCAGGCCCAGGGCATCCTGCTAGAAAATCCCGCGGCCGAGCTGCAGTTCCGGAACGGC
AGTGTCACGTCGTCGGGACAGTTGTCCGACGATGGCATCCGGCGCTTTCTGGGCACCGTCACCGTCAAGG
CCGGCAAGCTGGTCGCCGATCACGCCACGCTGGCCAACGTTGGCGACACCTGGGACGACGACGGCATCGC
GCTCTATGTGGCCGGCGAACAGGCCCAGGCCAGCATCGCCGACAGCACCCTGCAGGGCGCTGGCGGCGTG
CAGATCGAGCGCGGCGCCAATGTCACGGTCCAACGCAGCGCCATCGTCGACGGGGGCTTGCATATCGGCG
CCCTGCAGTCATTGCAGCCGGAAGACCTTCCGCCCAGCCGGGTGGTGCTGCGCGACACCAACGTGACCGC
CGTGCCCGCCAGCGGCGCGCCCGCGGCGGTGTCTGTGTTGGGGGCCAGTGAGCTTACGCTCGACGGCGGG
CACATCACCGGCGGGCGGGCAGCGGGGGTGGCGGCCATGCAAGGGGCGGTCGTGCATCTGCAGCGCGCGA
CGATACGGCGCGGGGACGCGCCTGCCGGCGGTGCGGTTCCCGGCGGTGCGGTTCCCGGTGGTGCGGTTCC
CGGCGGCTTCGGTCCCGGCGGCTTCGGTCCCGTCCTCGACGGCTGGTATGGCGTGGACGTATCGGGCTCC
AGCGTGGAGCTCGCCCAGTCGATCGTCGAGGCGCCGGAGCTGGGCGCCGCAATCCGGGTGGGCCGCGGCG
CCAGGGTGACGGTGTCGGGCGGCAGCTTGTCCGCACCGCACGGCAATGTCATCGAGACCGGCGGCGCGCG
TCGCTTTGCGCCTCAAGCCGCGCCCCTGTCGATCACCTTGCAGGCCGGCGCGCATGCCCAGGGGAAAGCG
CTGCTGTACCGGGTCCTGCCGGAGCCCGTGAAGCTGACGCTGACCGGGGGCGCCGATGCGCAGGGCGACA
TCGTCGCGACGGAGCTGCCCTCCATTCCCGGCACGTCGATCGGGCCGCTCGACGTGGCGCTGGCCAGCCA
GGCCCGATGGACGGGCGCTACCCGCGCGGTCGACTCGCTGTCCATCGACAACGCCACCTGGGTCATGACG
GACAACTCGAACGTCGGTGCGCTACGGCTGGCCAGCGACGGCAGCGTCGATTTCCAGCAGCCGGCCGAAG
CTGGGCGGTTCAAGGTCCTGACGGTCAATACGCTGGCGGGTTCGGGGCTGTTCCGCATGAATGTCTTCGC
GGACCTGGGGCTGAGCGACAAGCTGGTCGTCATGCAGGACGCCAGCGGCCAGCACAGGCTGTGGGTCCGC
AACAGCGGCAGCGAGCCGGCCAGCGCCAACACCCTGCTGCTGGTGCAGACGCCACTAGGCAGCGCGGCGA
CCTTTACCCTTGCCAACAAGGACGGCAAGGTCGATATCGGTACCTATCGCTATCGATTGGCCGCCAACGG
CAATGGGCAGTGGAGCCTGGTGGGCGCGAAGGCGCCGCCGGCGCCCAAGCCCGCGCCGCAGCCGGGTCCC
CAGCCGCCGCAGCCGCCGCAGCCGCAGCCGGAAGCGCCGGCGCCGCAACCGCCGGCGGGCAGGGAGTTGT
CCGCCGCCGCCAACGCGGCGGTCAACACGGGTGGGGTGGGCCTGGCCAGCACGCTCTGGTACGCCGAAAG
CAATGCGTTGTCCAAGCGCCTGGGCGAGTTGCGCCTGAATCCGGACGCCGGCGGCGCCTGGGGCCGCGGC
TTCGCGCAACGCCAGCAGCTGGACAACCGCGCCGGGCGGCGCTTCGACCAGAAGGTGGCCGGCTTCGAGC
TGGGCGCCGACCACGCGGTGGCGGTGGCCGGCGGACGCTGGCACCTGGGCGGGCTGGCCGGCTATACGCG
CGGCGACCGCGGCTTCACCGGCGACGGCGGCGGCCACACCGACAGCGTGCATGTCGGGGGCTATGCCACA
TATATCGCCGACAGCGGTTTCTACCTGGACGCGACGCTGCGCGCCAGCCGCCTGGAGAATGACTTCAAGG
TGGCGGGCAGCGACGGGTACGCGGTCAAGGGCAAGTACCGCACCCATGGGGTGGGCGCCTCGCTCGAGGC
GGGCCGGCGCTTTACCCATGCCGACGGCTGGTTCCTCGAGCCGCAGGCCGAGCTGGCGGTATTCCGGGCC
GGCGGCGGTGCGTACCGCGCGGCCAACGGCCTGCGGGTGCGCGACGAAGGCGGCAGCTCGGTGCTGGGTC
GCCTGGGCCTGGAGGTCGGCAAGCGCATCGAACTGGCAGGCGGCAGGCAGGTGCAGCCATACATCAAGGC
CAGCGTGCTGCAGGAGTTCGACGGCGCGGGTACGGTACACACCAACGGCATCGCGCACCGCACCGAACTG
CGCGGCACGCGCGCCGAACTGGGCCTGGGCATGGCCGCCGCGCTGGGCCGCGGCCACAGCCTGTATGCCT
CGTACGAGTACTCCAAGGGCCCGAAGCTGGCCATGCCGTGGACCTTCCACGCGGGCTACCGGTACAGCTG
GTA
>NP_879839.1 pertactin autotransporter [Bordetella pertussis Tohama I]
MNMSLSRIVKAAPLRRTTLAMALGALGAAPAAHADWNNQSIVKTGERQHGIHIQGSDPGGVRTASGTTIK
VSGRQAQGILLENPAAELQFRNGSVTSSGQLSDDGIRRFLGTVTVKAGKLVADHATLANVGDTWDDDGIA
LYVAGEQAQASIADSTLQGAGGVQIERGANVTVQRSAIVDGGLHIGALQSLQPEDLPPSRVVLRDTNVTA
VPASGAPAAVSVLGASELTLDGGHITGGRAAGVAAMQGAVVHLQRATIRRGDAPAGGAVPGGAVPGGAVP
GGFGPGGFGPVLDGWYGVDVSGSSVELAQSIVEAPELGAAIRVGRGARVTVSGGSLSAPHGNVIETGGAR
RFAPQAAPLSITLQAGAHAQGKALLYRVLPEPVKLTLTGGADAQGDIVATELPSIPGTSIGPLDVALASQ
ARWTGATRAVDSLSIDNATWVMTDNSNVGALRLASDGSVDFQQPAEAGRFKVLTVNTLAGSGLFRMNVFA
DLGLSDKLVVMQDASGQHRLWVRNSGSEPASANTLLLVQTPLGSAATFTLANKDGKVDIGTYRYRLAANG
NGQWSLVGAKAPPAPKPAPQPGPQPPQPPQPQPEAPAPQPPAGRELSAAANAAVNTGGVGLASTLWYAES
NALSKRLGELRLNPDAGGAWGRGFAQRQQLDNRAGRRFDQKVAGFELGADHAVAVAGGRWHLGGLAGYTR
GDRGFTGDGGGHTDSVHVGGYATYIADSGFYLDATLRASRLENDFKVAGSDGYAVKGKYRTHGVGASLEA
GRRFTHADGWFLEPQAELAVFRAGGGAYRAANGLRVRDEGGSSVLGRLGLEVGKRIELAGGRQVQPYIKA
SVLQEFDGAGTVHTNGIAHRTELRGTRAELGLGMAAALGRGHSLYASYEYSKGPKLAMPWTFHAGYRYSW
Protective antigen
Researchers constructed isogenic mutants of B. pertussis Tohama expressing the alleles ptxA1 or ptxA2 and prn1 or prn2 and compared the efficacies of an acellular pertussis vaccine against the mutants in a mouse model. While the vaccine was effective against all of the B. pertussis strains regardless of the allele expression pattern, the strain expressing ptxA1 and prn2 displayed a survival advantage over the other strains [Ref1021:Komatsu et al., 2010].
PtxA
Bordetella pertussis Tohama I
VO_0011034
2665068
33594638
BP3783
BX470248
NP_882282
257313
3988257
3989066
+
pertussis toxin subunit 1
7.54
27989.63
269
Previously sequenced as Bordetella pertussis pertussis toxin subunit 1 precursor, NAD-dependent ADP-ribosyltransferase, PtxA SW:TOX1_BORPE (P04977) (269 aa) fasta scores: E(): 1.5e-110, 100% id in 269 aa
>NC_002929.2:3988257-3989066 Bordetella pertussis Tohama I chromosome, complete genome
GATGCGTTGCACTCGGGCAATTCGCCAAACCGCAAGAACAGGCTGGCTGACGTGGCTGGCGATTCTTGCC
GTCACGGCGCCCGTGACTTCGCCGGCATGGGCCGACGATCCTCCCGCCACCGTATACCGCTATGACTCCC
GCCCGCCGGAGGACGTTTTCCAGAACGGATTCACGGCGTGGGGAAACAACGACAATGTGCTCGACCATCT
GACCGGACGTTCCTGCCAGGTCGGCAGCAGCAACAGCGCTTTCGTCTCCACCAGCAGCAGCCGGCGCTAT
ACCGAGGTCTATCTCGAACATCGCATGCAGGAAGCGGTCGAGGCCGAACGCGCCGGCAGGGGCACCGGCC
ACTTCATCGGCTACATCTACGAAGTCCGCGCCGACAACAATTTCTACGGCGCCGCCAGCTCGTACTTCGA
ATACGTCGACACTTATGGCGACAATGCCGGCCGTATCCTCGCCGGCGCGCTGGCCACCTACCAGAGCGAA
TATCTGGCACACCGGCGCATTCCGCCCGAAAACATCCGCAGGGTAACGCGGGTCTATCACAACGGCATCA
CCGGCGAGACCACGACCACGGAGTATTCCAACGCTCGCTACGTCAGCCAGCAGACTCGCGCCAATCCCAA
CCCCTACACATCGCGAAGGTCCGTAGCGTCGATCGTCGGCACATTGGTGCGCATGGCGCCGGTGATAGGC
GCTTGCATGGCGCGGCAGGCCGAAAGCTCCGAGGCCATGGCAGCCTGGTCCGAACGCGCCGGCGAGGCGA
TGGTTCTCGTGTACTACGAAAGCATCGCGTATTCGTTCTA
>NP_882282.1 pertussis toxin subunit 1 [Bordetella pertussis Tohama I]
MRCTRAIRQTARTGWLTWLAILAVTAPVTSPAWADDPPATVYRYDSRPPEDVFQNGFTAWGNNDNVLDHL
TGRSCQVGSSNSAFVSTSSSRRYTEVYLEHRMQEAVEAERAGRGTGHFIGYIYEVRADNNFYGAASSYFE
YVDTYGDNAGRILAGALATYQSEYLAHRRIPPENIRRVTRVYHNGITGETTTTEYSNARYVSQQTRANPN
PYTSRRSVASIVGTLVRMAPVIGACMARQAESSEAMAAWSERAGEAMVLVYYESIAYSF
Protective antigen
BALB/c mice were immunized with PTx vaccine on day 6 of life and then challenged with B. pertussis using the aerosol challenge model. These primed mice were significantly better protected against leukocytosis, weight loss, and proliferation of B. pertussis in the lungs following aerosol challenge than the nonprimed group. This protection correlated with levels of anti-PT antibody in serum present on the day of aerosol challenge [Ref1025:Bruss and Siber, 2002].
ptxB
Bordetella pertussis
VO_0011037
225311180
CDD:308828
CDD:280986
GOA:C0MPK7
InterPro:IPR003899
InterPro:IPR005138
InterPro:IPR008992
InterPro:IPR016187
InterPro:IPR020063
UniProtKB/TrEMBL:C0MPK7
520
?
pertussis toxin subunit 2 precursor
8.37
23698.772
302
Aerolysin/Pertussis toxin (APT) domain; pfam03440
>CAX52304.1 pertussis toxin subunit 2 precursor [Bordetella pertussis]
MPIDRKTLCHLLSVLPLALLGSHVARASTPGIVIPPQEQITQHGGPYGRCANKTRALTVAELRGSGDLQE
YLRHVTRGWSIFALYDGTYLGGEYGGVIKDGTPGGAFDLKTTFCIMTTRNTGQPATDHYYSNVTATRLLS
STNSRLCAVFVRSGQPVIGACTSPYDGKYWSMYSRLRKMLYLIYVAGISVRVHVSKEEQYYDYEDATFET
YALTGISICNPGSSLC
Protective antigen
BALB/c mice were immunized with PTx vaccine on day 6 of life and then challenged with B. pertussis using the aerosol challenge model. These primed mice were significantly better protected against leukocytosis, weight loss, and proliferation of B. pertussis in the lungs following aerosol challenge than the nonprimed group. This protection correlated with levels of anti-PT antibody in serum present on the day of aerosol challenge [Ref1025:Bruss and Siber, 2002].
ptxC
Bordetella pertussis
VO_0011038
225311183
CDD:308828
CDD:280986
GOA:Q546I1
InterPro:IPR003899
InterPro:IPR005138
InterPro:IPR008992
InterPro:IPR016187
InterPro:IPR020063
UniProtKB/TrEMBL:Q546I1
520
?
pertussis toxin subunit 3 precursor
8.76
24184.712
303
Aerolysin/Pertussis toxin (APT) domain; pfam03440
>CAX52307.1 pertussis toxin subunit 3 precursor [Bordetella pertussis]
MLINNKKLLHHILPILVLALLGMRTAQAVAPGIVIPPKALFTQQGGAYGRCPNGTRALTVAELRGNAELQ
TYLRQITPGWSIYGLYDGTYLGQAYGGIIKDAPPGAGFIYRETFCITTIYKTGQPAADHYYSKVTATRLL
ASTNSRLCAVFVRDGQSVIGACASPYEGRYRDMYDALRRLLYMIYMSGLAVRVHVSKEEQYYDYEDATFQ
TYALTGISLCNPAASIC
Protective antigen
BALB/c mice were immunized with PTx vaccine on day 6 of life and then challenged with B. pertussis using the aerosol challenge model. These primed mice were significantly better protected against leukocytosis, weight loss, and proliferation of B. pertussis in the lungs following aerosol challenge than the nonprimed group. This protection correlated with levels of anti-PT antibody in serum present on the day of aerosol challenge [Ref1025:Bruss and Siber, 2002].
ptxD
Bordetella pertussis
VO_0011032
225311181
CDD:286372
GOA:C0MPK8
InterPro:IPR008992
InterPro:IPR015355
UniProtKB/TrEMBL:C0MPK8
520
?
pertussis toxin subunit 4 precursor
10.82
15542.962
227
Pertussis toxin S4 subunit; pfam09275
>CAX52305.1 pertussis toxin subunit 4 precursor [Bordetella pertussis]
MLRRFPTRTTAPGQGGARRSRVRALAWLLASGAMTHLSPALADVPYVLVKTNMVVTSVAMKPYEVTPTRM
LVCGIAAKLGAAASSPDAHVPFCFGKDLKRPGSSPMEVMLRAVFMQQRPLRMFLGPKQLTFEGKPALELI
RMVECSGKQDCP
Protective antigen
BALB/c mice were immunized with PTx vaccine on day 6 of life and then challenged with B. pertussis using the aerosol challenge model. These primed mice were significantly better protected against leukocytosis, weight loss, and proliferation of B. pertussis in the lungs following aerosol challenge than the nonprimed group. This protection correlated with levels of anti-PT antibody in serum present on the day of aerosol challenge [Ref1025:Bruss and Siber, 2002].
ptxE
Bordetella pertussis
VO_0011039
225311182
CDD:286373
GOA:C0MPK9
InterPro:IPR008992
InterPro:IPR015356
UniProtKB/TrEMBL:C0MPK9
520
?
pertussis toxin subunit 5 precursor
6.49
14292.102
207
Pertussis toxin S5 subunit; pfam09276
>CAX52306.1 pertussis toxin subunit 5 precursor [Bordetella pertussis]
MQRQAGLPLKANPMHTIASILLSVLGIYSPADVAGLPTHLYKNFTVQELALKLKGKNQEFCLTAFMSGRS
LVRACLSDAGHEHDTWFDTMLGFAISAYALKSRIALTVEDSPYPGTPGDLLELQICPLNGYCE
Protective antigen
BALB/c mice were immunized with PTx vaccine on day 6 of life and then challenged with B. pertussis using the aerosol challenge model. These primed mice were significantly better protected against leukocytosis, weight loss, and proliferation of B. pertussis in the lungs following aerosol challenge than the nonprimed group. This protection correlated with levels of anti-PT antibody in serum present on the day of aerosol challenge [Ref1025:Bruss and Siber, 2002].
S1
Bordetella pertussis Tohama
3152313
CDD:111768
GOA:Q599G4
HSSP:P04977
InterPro:IPR003898
UniProtKB/TrEMBL:Q599G4
520
?
toxin subunit S1
7.49
28321.94
326
Pertussis toxin, subunit 1; pfam02917
>CAA06899.1 toxin subunit S1 [Bordetella pertussis]
MRCTRAIRQTARTGWLTWLAILAVTAPVTSPAWADDPPATVYRYDSRPPEDVFQNGFTAWGNNDNVLDHL
TGRSCQVGSSNSAFVSTSSSRRYTEVYLEHRMQEAVEAERAGRGTGHFIGYIYEVRADNNFYGAASSYFE
YVDTYGDNAGRILAGALATYQSEYLAHRRIPPENIRRVTRVYHNGITGETTTTEYSNARYVSQQTRANPN
PYTSRRSVASIVGTLVRMAPVIGACMARQAESSEAMAAWSERAGEAMVLVYYESIAYSF
Protective antigen
TcfA
Bordetella pertussis
282766137
CDD:154874
520
?
tracheal colonization factor
5.91
62423.78
631
Autotransporter beta-domain; cl02365
>gi|282766137|gb|ADA85103.1| tracheal colonization factor [Bordetella pertussis]
MHIYGNMNRATPCRGAVRALALALLGAGMWTLSPPSAWALKLPSLLTDDELKLVLPTGMSLEDFKRSLQE
SAPSALATPPSSSPPVAKPGPGSVAEAPSGSGHKDNPSPPVVGVGPGMAESSGGHNPGVGGGTHENGLPG
IGKVGGSAPGPDTSTGSGPDAGMASGAGSTSPGASGGAGKDAMPPSEGERPDSGMSDSGRGGESSAGGLN
PDGAGKPPREEGEPGSKSPADGGQDGPPPPRDGGDADPQPPRDDGNGEQQPPKGGGDEGQRPPPAAGNGG
NGGNGNAQLPERGDDAGPKPPEGEGGDEGPQPPQGGGEQDAPEVPPVAPAPPAGNGVYDPGTHTLTTPAS
AAVSLASSSHGVWQAEMNALSKRMGELRLTPVAGGVWGRAFGRRQDVDNRVSREFRQTISGFELGADTAL
PVADGRWHVGAVAGYTNGRIKFDRGGTGDDDSVHVGAYATYIEDGGFYMDGIVRVSRIRHAFKVDDAKGR
RVRGQYRGNGVGASLELGKRFTWPGAWYVEPQLEVAAFHAQGADYTASNGLRIKDDGTNSMLGRLGLHVG
RQFDLGDGRVVQPYMKLSWVQEFDGKGTVRTNDIRHKVRLDGGRTELAVGVASQLGKHGSLFGSYEYAKG
S
Other
Intranasal administration of IEM101 expressing Tcf induced a significant reduction in bacterial colonization of the tracheas of mice challenged with wild-type B. pertussis. These data are in agreement with the putative role of Tcf in Bordetella tracheal colonization [Ref1027:Chen et al., 1998].
Bruss and Siber, 2002
journal
Bruss JB, Siber GR
Quantitative priming with inactivated pertussis toxoid vaccine in the aerosol challenge model
2002
70
8
4600-4608
Infection and immunity
Cainelli et al., 2007
journal
Cainelli Gebara VC, Risoléo L, Lopes AP, Ferreira VR, Quintilio W, Lépine F, Silva WD, Raw I
Adjuvant and immunogenic activities of the 73kDa N-terminal alpha-domain of BrkA autotransporter and Cpn60/60kDa chaperonin of Bordetella pertussis
2007
25
4
621-629
Vaccine
Chen et al., 1998
journal
Chen I, Finn TM, Yanqing L, Guoming Q, Rappuoli R, Pizza M
A recombinant live attenuated strain of Vibrio cholerae induces immunity against tetanus toxin and Bordetella pertussis tracheal colonization factor
1998
66
4
1648-1653
Infection and immunity
FDA: Adacel
website
FDA: Adacel
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172481.htm
FDA: Boostrix
website
FDA: Boostrix
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172925.htm
FDA: DAPTACEL
website
FDA: DAPTACEL
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101572.htm
FDA: Infanrix
website
FDA: Infanrix
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101568.htm
FDA: KINRIX
website
FDA: KINRIX vaccine information
https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM241453.pdf
FDA: Pediarix
website
FDA: Pediarix
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm146759.htm
FDA: Pentacel
website
FDA: Pentacel
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172502.htm
FDA: Quadracel
website
FDA: Quadracel vaccine information
https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM439903.pdf
FDA: Tripedia
website
FDA: Tripedia
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101565.htm
Fennelly et al., 2008
journal
Fennelly NK, Sisti F, Higgins SC, Ross PJ, van der Heide H, Mooi FR, Boyd A, Mills KH
Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses
2008
76
3
1257-1266
Infection and immunity
Feunou et al., 2008
journal
Feunou PF, Ismaili J, Debrie AS, Huot L, Hot D, Raze D, Lemoine Y, Locht C
Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1
2008
26
45
5722-5727
Vaccine
GSK: Boostrix-Polio
website
GSK: Boostrix-Polio vaccine information
https://ca.gsk.com/media/589683/boostrix-polio.pdf
GSK: Infanrix-hexa
website
GSK: Infanrix-hexa vaccine information
http://ca.gsk.com/media/537989/infanrix-hexa.pdf
GSK: Infanrix-IPV
website
GSK: Infanrix-IPV vaccine information
http://ca.gsk.com/media/590851/infanrix-ipv.pdf
GSK: Infanrix-IPV/Hib
website
GSK: Infanrix-IPV/Hib vaccine information
http://ca.gsk.com/media/590970/infanrix-ipv-hib.pdf
Guiso et al., 1989
journal
Guiso N, Rocancourt M, Szatanik M, Alonso JM
Bordetella adenylate cyclase is a virulence associated factor and an immunoprotective antigen
1989
7
5
373-380
Microbial pathogenesis
Kamachi et al., 2003
journal
Kamachi K, Konda T, Arakawa Y
DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice
2003
21
31
4609-4615
Vaccine
Kinnear et al., 2001
journal
Kinnear SM, Marques RR, Carbonetti NH
Differential regulation of Bvg-activated virulence factors plays a role in Bordetella pertussis pathogenicity
2001
69
4
1983-1993
Infection and immunity
Komatsu et al., 2010
journal
Komatsu E, Yamaguchi F, Abe A, Weiss AA, Watanabe M
Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model
2010
17
5
807-812
Clinical and vaccine immunology : CVI
Lee et al., 1999
journal
Lee SF, March RJ, Halperin SA, Faulkner G, Gao L
Surface expression of a protective recombinant pertussis toxin S1 subunit fragment in Streptococcus gordonii
1999
67
3
1511-1516
Infection and immunity
Merkel et al., 1998
journal
Merkel TJ, Stibitz S, Keith JM, Leef M, Shahin R
Contribution of regulation by the bvg locus to respiratory infection of mice by Bordetella pertussis
1998
66
9
4367-4373
Infection and immunity
Mielcarek et al., 2006
journal
Mielcarek N, Debrie AS, Raze D, Quatannens J, Engle J, Goldman WE, Locht C
Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation
2006
24 Suppl 2
S2-54-5
Vaccine
Nascimento et al., 2008
journal
Nascimento IP, Dias WO, Quintilio W, Christ AP, Moraes JF, Vancetto MD, Ribeiro-Dos-Santos G, Raw I, Leite LC
Neonatal immunization with a single dose of recombinant BCG expressing subunit S1 from pertussis toxin induces complete protection against Bordetella pertussis intracerebral challenge
2008
10
2
198-202
Microbes and infection / Institut Pasteur
Novotny et al., 1985
journal
Novotny P, Chubb AP, Cownley K, Montaraz JA, Beesley JE
Bordetella adenylate cyclase: a genus specific protective antigen and virulence factor
1985
61
27-41
Developments in biological standardization
Novotny et al., 1991
journal
Novotny P, Chubb AP, Cownley K, Charles IG
Biologic and protective properties of the 69-kDa outer membrane protein of Bordetella pertussis: a novel formulation for an acellular pertussis vaccine
1991
164
1
114-122
The Journal of infectious diseases
Product Monograph: Adacel-Polio
website
Product Monograph: Adacel-Polio vaccine information
https://www.vaccineshoppecanada.com/document.cfm?file=adacel-polio_e.pdf
Product Monograph: Pediacel
website
Product Monograph: Pediacel vaccine information
https://www.vaccineshoppecanada.com/document.cfm?file=Pediacel_E.pdf
Roberts et al., 1990
journal
Roberts M, Maskell D, Novotny P, Dougan G
Construction and characterization in vivo of Bordetella pertussis aroA mutants
1990
58
3
732-739
Infection and immunity
Salyers and Whitt., 2002
book
Abigail A. Salyers, Dixie D. Whitt
Bordetella pertussis
2002
263-73
Bacterial Pathogenesis: A Molecular Approach
ASM Press
Washington D.C. USA
1-55581-171-x
Sato and Sato, 1984
journal
Sato H, Sato Y
Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system
1984
46
2
415-421
Infection and immunity
Sukumar et al., 2007
journal
Sukumar N, Mishra M, Sloan GP, Ogi T, Deora R
Differential Bvg phase-dependent regulation and combinatorial role in pathogenesis of two Bordetella paralogs, BipA and BcfA
2007
189
10
3695-3704
Journal of bacteriology
Wiki: Bordetella pertussis
website
Bordetella pertussis
http://en.wikipedia.org/wiki/Bordetella_pertussis